Know Cancer

forgot password

Saliva mRNA Expression Profiling for Early Stage Non-Small Cell Lung Cancer Screening

40 Years
79 Years
Not Enrolling
Non-Small Cell Lung Cancer

Thank you

Trial Information

Saliva mRNA Expression Profiling for Early Stage Non-Small Cell Lung Cancer Screening

Inclusion Criteria:

1. Patients with untreated stage I-II NSCLC OR Healthy control subjects: with a > 20
pack year history of cigarette smoking OR Never smokers (defined as less than 100
cigarettes over subject's lifetime)

- The investigators recognize that pathologic confirmation is not always available
prior to surgical resection of a lung mass. To account for this, subjects with
a suspicious lung mass concerning for lung cancer, can be enrolled on this
trial, and submit a saliva sample prior to surgical resection (ideally within 45
days of planned surgery).

2. Adults age 40-79

3. Ability to understand the investigational nature of the study and sign the informed
consent in accordance with institutional and FDA guidelines

Exclusion Criteria:

1. No active pulmonary infection, i.e. bronchitis or pneumonia for 6 months

2. No use of steroid inhalers for > 6 months

3. No other prior malignancy is allowed except for adequately treated basal or squamous
cell skin cancer, in situ cervical cancer, or other cancers from which the patient
has been disease-free for 5 years

Type of Study:


Study Design:

Observational Model: Case Control

Principal Investigator

Glen J Weiss, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

TGen Clinical Research Services at Scottsdale Healthcare


United States: Institutional Review Board

Study ID:




Start Date:

August 2007

Completion Date:

July 2008

Related Keywords:

  • Non-Small Cell Lung Cancer
  • non-small cell lung cancer
  • screening
  • saliva
  • gene expression
  • healthy control subject
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms